

# SIMULATION OF THE DRUG DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE


Chiara Piazzola, Christian Muench,  
Martina Prugger, Sanja Ružićić,

INSTRUCTOR: Prof. Paola Causin

University of Innsbruck, TU Munich  
University of Innsbruck, University of Novi Sad  
University of Milano

September 10, 2016

# Anatomy of the eye and drug delivery techniques




**DISEASES** affecting the posterior segment of the eye

- ▶ age related macular degeneration (AMD) and
- ▶ diabetic retinopathy

are the main **CAUSES OF BLINDNESS** in developed countries.

Copyright Informa 2014:  
doi/abs/10.1517/17425247.2014.935338

# The Structure of the Eye – PSE



- ▶ **SCLERA (S)** – the white part of the eye, relatively permeable to molecules.
- ▶ **CHOROID (C)** – a dense network of large and small blood vessels with a relatively sparse population of cells.

- ▶ **RETINA (R)** – a layer tissue containing neural cells.
- ▶ **VITREOUS (V)** – clear, jelly-like substance that fills the middle of the eye.

# Therapeutic Treatments

## POSSIBLE THERAPEUTIC TREATMENTS

- ▶ topical ocular eye drops

PROBLEM: *Most of the drug is cleared by tears and therapeutic levels near the retina may not be reached!*

- ▶ high drug doses given intravenously or by intravitreal administration (intravitreal injections).
- ▶ drugs release from an implant in the vitreous.

## GOAL

- ▶ maximize the therapeutic benefits
- ▶ minimize potential adverse effects such as possible tissue damage caused by excessively high concentration of drugs

# Barriers in the drug delivery

- ▶ **STATIC BARRIERS** such as physical obstacles to drug diffusion such as the sclera itself, the retinal pigment epithelium and the retinal vessels.
- ▶ **DYNAMIC BARRIERS** include drug clearance mechanisms through blood and lymphatic vessels and degradation processes.
  - ▶ Drug solubility,
  - ▶ charge,
  - ▶ degree of ionization,
  - ▶ molecular size and shape
  - ▶ ...

affect the penetration rate of the drug across the various barriers.

# Mathematical model of the drug release to the posterior segment of the eye

## Model of PSE

$$\frac{\partial C_j}{\partial t} - D_j \frac{\partial^2 C_j}{\partial z^2} + \beta_j \frac{\partial C_j}{\partial z} = Q(C_j), \quad j = S, C, R, V$$

$C_j = C_j(t, x) [g/cm^3]$  ... the drug concentration in layer  $j$ ,

$D_j \equiv D [cm^2/s]$  ... drug diffusivity rate,

$\beta [cm/s]$  ... advection parameter,

$$Q(C_j) = \begin{cases} -k_j C_j, & k > 0 \\ \bar{Q} = \text{constant} & \end{cases} \quad \dots \text{reaction term}$$

# Spatial discretization: finite elements

## EXAMPLE:

$$\begin{aligned}u''(x) &= f(x) \text{ in } (0, 1), \\u(0) &= 0, \\u(1) &= 0.\end{aligned}$$

## WEAK FORMULATION:

$$\begin{aligned}\int_0^1 u''(x)v(x)dx &= u'(x)v(x)|_0^1 - \int_0^1 u'(x)v'(x)dx \\&= -\phi(u, v).\end{aligned}$$

# Spatial discretization: finite elements

We divide the interval  $(0, 1)$  such that

$$0 = x_0 < x_1 < \dots < x_n < x_{n+1} = 1$$




Figure: Possible form of test function  $v$

$$u(x) \approx \sum_{k=1}^n u_k v_k(x), \quad f(x) \approx \sum_{k=1}^n f_k v_k(x)$$

Using

$$\phi(v_i, v_j) = \int_0^1 v'_i v'_j dx,$$

the approximated equation becomes

$$-\sum_{k=1}^n u_k \phi(v_k, v_j) = \sum_{k=1}^n f_k \int v_k v_j.$$

This can be written in the **matrix form**

$$-Lu = Mf$$

where

$$\mathbf{u} = (u_1, \dots, u_n)' \text{ and } \mathbf{f} = (f_1, \dots, f_n)'$$

$$L_{ij} = \phi(v_i, v_j), \quad M_{ij} = \int v_i v_j$$

# Time discretization: Theta method

## EXAMPLE:

$$\begin{aligned}\mathbf{y}' &= \mathbf{f}(t, \mathbf{y}) \\ \mathbf{y}(0) &= 0,\end{aligned}$$

where  $\mathbf{y}$  and  $\mathbf{f}$  are vectors depending on time  $t \geq 0$ .

To approximate the solution at the next time level  $t_{n+1} = t_n + \Delta t$ , we use a method of the form

$$y_{n+1} = y_n + \Delta t[\theta f(t_n, y_n) - (1 - \theta)f(t_{n+1}, y_{n+1})],$$

where  $n = 0, 1, \dots$  and  $\theta \in [0, 1]$ .

# Implement the Neumann Boundary Condition


## CONTINUITY OF FLUXES

$$\frac{\partial u_L}{\partial n_L} = \frac{\partial u_R}{\partial n_L},$$

Approximation by


$$\frac{\partial u_R}{\partial n_L} \approx \frac{u_{R1} - u_{R0}}{\Delta x},$$

where  $\Delta x = \frac{b_2 - a_2}{N_2}$ .



# Algorithm

1. set a tolerance  $TOL = 10^{-4}$
2. use  $u_{R0}^0$  and  $u_{R1}^0$  from initial condition and compute derivative
3. set  $u_{R0}^k = u_{R0}^0$ ,  $u_{R1}^k = u_{R1}^0$  and  $k = 0$
4. set  $u^{k+1} = pu^0 + (1 - p)u^k$ , with  $p \in (0, 1)$ ,
5. compute difference  $diff = \|u^{k+1} - u^k\|_\infty$
6. if  $diff < TOL$ , accept result
7. else, set  $u_{R0}^k = u_{R0}^{k+1}$ ,  $u_{R1}^k = u_{R1}^{k+1}$  and  $k = k + 1$  and go to 4.



# Mathematical model of the drug release to the posterior segment of the eye

## Model of PSE

$$\frac{\partial C_j}{\partial t} - D_j \frac{\partial^2 C_j}{\partial z^2} + \beta_j \frac{\partial C_j}{\partial z} = Q(C_j), \quad j = S, C, R, V$$

$C_j = C_j(t, x)[g/cm^3]$  ... the drug concentration in layer  $j$ ,

$D_j \equiv D [cm^2/s]$  ... drug diffusivity rate,

$\beta [cm/s]$  ... advection parameter,

$$Q(C_j) = \begin{cases} -k_j C_j, & k > 0 \\ \bar{Q} = \text{constant} & \end{cases} \quad \dots \text{reaction term}$$

## Sclera

$$\frac{\partial C_S}{\partial t} - D_S \frac{\partial^2 C_S}{\partial z^2} = -\kappa_S C_S,$$

$\kappa_S$  ... decay coefficient

## BOUNDARY AND INTERFACE CONDITIONS

Dirichlet:  $C_S = c(t)$

Neumann condition – Continuity of fluxes

$$D_S \frac{\partial C_S}{\partial z} \cdot n_S = D_C \frac{\partial C_C}{\partial z} \cdot n_S$$

## Choroid

$$\frac{\partial C_C}{\partial t} - D_C \frac{\partial^2 C_C}{\partial z^2} = -\kappa_C C_C,$$

$\kappa_C$  ... decay coefficient

INTERFACE CONDITIONS:

Robin condition – Permeability law

$$-D_C \frac{\partial C_C}{\partial z} \cdot n_C = L_p(C_C - C_S)$$

$L_p$  [cm/s] ... membrane permeability coefficient

Neumann condition – Continuity of fluxes

$$D_C \frac{\partial C_C}{\partial z} \cdot n_C = D_R \frac{\partial C_R}{\partial z} \cdot n_C$$

## Retina

$$\frac{\partial C_R}{\partial t} - D_R \frac{\partial^2 C_R}{\partial z^2} + \beta_R \frac{\partial C_R}{\partial z} = -\kappa_R C_R,$$

$\kappa_R$  ... decay coefficient

$\beta_R$  ... pumping velocity

### INTERFACE CONDITIONS:

Robin condition – Permeability law

$$-D_R \frac{C_R}{\partial z} \cdot n_R = L_p(C_R - C_C)$$

Neumann condition – Continuity of fluxes

$$D_R \frac{\partial C_R}{\partial z} \cdot n_R = D_V \frac{\partial C_V}{\partial z} \cdot n_R$$

## Vitreous

$$\frac{\partial C_V}{\partial t} - D_V \frac{\partial^2 C_V}{\partial z^2} = -\kappa_V C_V,$$

$\kappa_V$  ... decay coefficient

### INTERFACE AND BOUNDARY CONDITIONS:

Robin condition – Permeability law

$$-D_V \frac{C_V}{\partial z} \cdot n_v = L_p(C_V - C_R)$$

Neumann condition

$$\frac{\partial C_V}{\partial z} = 0$$

# Table of parameters

| DESCRIPTION                   | PAR.      | UNIT     | VALUE                 |
|-------------------------------|-----------|----------|-----------------------|
| SCLERA THICKNESS              | $l_S$     | $\mu m$  | 600                   |
| CHOROID THICKNESS             | $l_C$     | $\mu m$  | 300                   |
| RETINA THICKNESS              | $l_R$     | $\mu m$  | 246                   |
| VITREOUS THICKNESS            | $l_V$     | $\mu m$  | 15000                 |
| Drug DIFFUSIVITY coefficient  | $D$       | $cm^2/s$ | $10^{-6}$             |
| PERMEABILITY coefficient      | $L_p$     | $cm/s$   | $10^{-5}$             |
| ADVECTION coefficient         | $\beta_R$ | $cm/s$   | $-2.44 \cdot 10^{-5}$ |
| DECAY coefficient in sclera   | $k_S$     | $1/s$    | $3 \cdot 10^{-4}$     |
| DECAY coefficient in choroid  | $k_C$     | $1/s$    | $3 \cdot 10^{-4}$     |
| DECAY coefficient in retina   | $k_R$     | $1/s$    | $3 \cdot 10^{-4}$     |
| DECAY coefficient in vitreous | $k_C$     | $1/s$    | $8 \cdot 10^{-5}$     |

- ▶ We focused on the one dimensional problem;
- ▶ At the sclera external boundary we impose a concentration exponentially decreasing in time fitting the trend obtained from a model of drug release in posterior eye gel implants (see [1]);
- ▶ Initial concentration is zero on all the domains;
- ▶ The problem is convection dominated.

-  Michail E. Kavousanakis, Nikolaos G. Kalogeropoulos, and Dimitrios T. Hatzivramidis. *Computational modeling of drug delivery to the posterior eye*. Chemical Engineering Science 108 (2014): 203-212.
-  Causin P., Malgaroli F. *Mathematical assessment of drug build-up in the posterior eye following transscleral delivery*. submitted to Journal of Mathematics in Industry, (2016).